What is OxyDial?
OxyDial Inc. is dedicated to revolutionizing healthcare diagnostics with its proprietary Oxygen-Hemoglobin Equilibrium blood testing instrument and associated cloud platform, currently in development. This cutting-edge technology promises to deliver faster, more accessible, and portable testing solutions, targeting critical areas such as genetic diseases and blood disorders. The company aims to empower researchers and healthcare providers by enhancing patient care and streamlining medical research workflows. OxyDial's commitment to superior customer support and ongoing innovation positions it as a key player in the medical technology sector.
How much funding has OxyDial raised?
OxyDial has raised a total of $700K across 1 funding round:
Private Equity
$700K
Private Equity (2026): $700K, investors not publicly disclosed
What's next for OxyDial?
The substantial enterprise-level funding and strategic investment signal a critical growth phase for OxyDial. This capital infusion is expected to accelerate the development and commercialization of their innovative blood testing instrument and platform. The company is poised to expand its market reach, further refine its technology, and solidify its position in the competitive healthcare diagnostics landscape. Future endeavors will likely focus on clinical validation, regulatory approvals, and strategic partnerships to bring their advanced solutions to a wider audience.
See full OxyDial company page
